Skip to content
Screener

Total Revenue at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$12.97B+5.7%
Eli Lilly logo
Eli LillyLLY
$22.97B+47.7%
Amgen logo
AmgenAMGN
$10.05B+9.5%
Incyte logo
IncyteINCY
$1.67B+37.7%
AbbVie logo
AbbVieABBV
$16.99B+10.2%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$65M+466%

Segments

By product

See full
Fusfertide Clinical Trial Supplies$11M

Other financials

Income statement

See full
Operating income$158.8M+478%
Net income$162.8M+568%
EPS (diluted)$2.29+516%

Balance sheet

See full
Cash & equivalents$420.1M+149%
Total debt$9.2M-18.3%
Total equity$841.5M+26.0%
Total assets$885.5M+23.3%

Cash flow

See full
Operating cash flow$219.1M
CapEx$168.0K-79.3%
Free cash flow$218.9M

Valuation

See full
Market cap$8.83B+165%
Enterprise value$8.42B+165%
P/E106.5×+42.4×
P/S31.3×+15.4×

Profitability

See full
Operating margin20.7%+9.2pp
Net margin29.4%+4.5pp
FCF margin-12,264.3%-12,527pp

Returns & leverage

See full
Return on equity11%+2.4pp
Debt / equity0.0×
Current ratio21.7×+4.7×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Protagonist Therapeutics’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:17 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-091123
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
License and collaboration revenue$213,475$5,546$269,843$33,867
Operating expenses:
Research and development42,06137,03688,80072,929
General and administrative12,64810,55125,92522,289
Total operating expenses54,70947,587114,72595,218
Income (loss) from operations158,766(42,041)155,118(61,351)
Interest income6,4297,40612,30514,979
Other (expense) income, net(81)36(28)118

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Protagonist Therapeutics's total revenue?
Protagonist Therapeutics (PTGX) reported total revenue of $213.48M in Q2 2026.
How has Protagonist Therapeutics's total revenue changed year-over-year?
Protagonist Therapeutics's total revenue increased by 3749.2% year-over-year, from $5.55M to $213.48M.
What is the long-term trend for Protagonist Therapeutics's total revenue?
Over 4 years (2021 to 2025), Protagonist Therapeutics's total revenue has grown at a 13.9% compound annual growth rate (CAGR), from $27.36M to $46.02M.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Protagonist Therapeutics's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude